Journal: iScience

Article Title: Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter study

doi: 10.1016/j.isci.2025.112986

Figure Lengend Snippet: Upregulation of 18 miRNAs in HCC patients (A) Study design of the current study. CQ, Chongqing; BJ, Beijing. (B) Volcano plot of differentially expressed miRNAs between HCC patients and LC patients in the discovery stage. The 16 validated miRNA targets were annotated. (C) Unsupervised hierarchical clustering of 18 miRNA targets across 354 matched samples in validation stage 1.

Article Snippet: 3 μL of extracted RNA was reverse transcribed using the miRCURY LNA RT Kit (Qiagen) in 10 μL reactions. cDNA was diluted 20× before qPCR. qPCR was performed using miRCURY LNA miRNA Probe PCR Assays (Qiagen).

Techniques: Biomarker Discovery

Journal: iScience

Article Title: Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter study

doi: 10.1016/j.isci.2025.112986

Figure Lengend Snippet: Forest plot of study-wide significant miRNAs in HCC CI, confidence interval; SMD, standardized mean difference. Upregulation of 4 miRNAs in our findings was validated through a meta-analysis.

Article Snippet: 3 μL of extracted RNA was reverse transcribed using the miRCURY LNA RT Kit (Qiagen) in 10 μL reactions. cDNA was diluted 20× before qPCR. qPCR was performed using miRCURY LNA miRNA Probe PCR Assays (Qiagen).

Techniques:

Journal: iScience

Article Title: Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter study

doi: 10.1016/j.isci.2025.112986

Figure Lengend Snippet: Diagnostic performance and risk score of combined panel across different sample sets (A) In the training set. (B) In the testing set. (C) In the validation set. (D) Risk score distribution of combined panel across patients with different HCC stages. The combined panel demonstrated superior diagnostic performance compared to AFP20 alone across all sample sets. miRNA panel: miR-361-5p+ miR-130a-3p+ miR-27a-3p+ miR-30d-5p+ miR-193a-5p. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 10 − 3 ; ∗∗∗∗ p < 10 − 4 .

Article Snippet: 3 μL of extracted RNA was reverse transcribed using the miRCURY LNA RT Kit (Qiagen) in 10 μL reactions. cDNA was diluted 20× before qPCR. qPCR was performed using miRCURY LNA miRNA Probe PCR Assays (Qiagen).

Techniques: Diagnostic Assay, Biomarker Discovery

Journal: iScience

Article Title: Establishing a miRNA panel for hepatocellular carcinoma screening through a multicenter study

doi: 10.1016/j.isci.2025.112986

Figure Lengend Snippet: Association of miRNAs with clinical parameters (A–C) Association with (A) different HCC stages, (B) tumor size, and (C) tumor invasion. 3 miRNAs (miR-130a-3p, miR-361-5p, and miR-27a-3p) in the panel demonstrated further upregulation in patients with late-stage HCC and larger tumor size. ns, not significant; ∗P adj < 0.05; ∗∗ P adj < 0.01; ∗∗∗ P adj < 10 −3 ; ∗∗∗∗ P adj < 10 −4 . (D) Interaction network of the 5 miRNAs in the panel and their target genes. Only genes targeted by 3 or more miRNAs are shown. (E) KEGG enrichment analysis for target genes of the 5-miRNA panel.

Article Snippet: 3 μL of extracted RNA was reverse transcribed using the miRCURY LNA RT Kit (Qiagen) in 10 μL reactions. cDNA was diluted 20× before qPCR. qPCR was performed using miRCURY LNA miRNA Probe PCR Assays (Qiagen).

Techniques: